Logo image
Efficiency of bis-amidate phosphonate prodrugs
Journal article   Peer reviewed

Efficiency of bis-amidate phosphonate prodrugs

Nicholas A Lentini, Xueting Huang, Megan A Schladetsch, Chia-Hung Christine Hsiao, David F Wiemer and Andrew J Wiemer
Bioorganic & medicinal chemistry letters, Vol.66, 128724
04/08/2022
DOI: 10.1016/j.bmcl.2022.128724
PMCID: PMC10245299
PMID: 35405283

View Online

Abstract

Bis-amidate derivatives have been viewed as attractive phosphonate prodrug forms because of their straightforward synthesis, lack of phosphorus stereochemistry, plasma stability and nontoxic amino acid metabolites. However, the efficiency of bis-amidate prodrug forms is unclear, as prior studies on this class of prodrugs have not evaluated their activation kinetics. Here, we synthetized a small panel of bis-amidate prodrugs of butyrophilin ligands as potential immunotherapy agents. These compounds were examined relative to other prodrug forms delivering the same payload for their stability in plasma and cell lysate, their ability to stimulate T cell proliferation in human PBMCs, and their activation kinetics in a leukemia co-culture model of T cell cytokine production. The bis-amidate prodrugs demonstrate high plasma stability and improved cellular phosphoantigen activity relative to the free phosphonic acid. However, the efficiency of bis-amidate activation is low relative to other prodrugs that contain at least one ester such as aryl-amidate, aryl-acyloxyalkyl ester, and bis-acyloxyalkyl ester forms. Therefore, bis-amidate prodrugs do not drive rapid cellular payload accumulation and they would be more useful for payloads in which slower, sustained-release kinetics are preferred.
phosphonamidate prodrug ligand butyrophilin isoprenoid phosphoantigen

Details

Metrics

Logo image